Consistent with the central role of angiogenesis in disease progression and survival, bevacizumab, a monoclonal antibody that targets VEGF, has been shown to be active in the management of both platinum-sensitive and platinum-resistant ovarian cancer with three large randomized controlled trials, confirming an additive benefit of anti-angiogenic therapy to chemotherapy [9–12]. The gene discussed is VEGFA; the disease is ovarian carcinoma.